Warm Autoimmune Hemolytic Anemia clinical trials

Explore recruiting warm autoimmune hemolytic anemia clinical trials.

Recruiting warm autoimmune hemolytic anemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Warm Autoimmune Hemolytic Anemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension

Hungary, Czechia, France, Greece, Netherlands, Poland +3 more

Phase II and Phase III (Integrated) EU CTIS Study details

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A SAFETY AND DOSE CONFIRMATION RUN-IN PERIOD, TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (SAPHIARE)

Spain, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (LUMINA 2)

Italy, Spain, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)

Germany, Hungary, Italy, Romania, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)

Germany, Czechia, Belgium, Spain, Italy, Bulgaria +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease

Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Warm Autoimmune Hemolytic Anemia trials by city

Warm Autoimmune Hemolytic Anemia in Toronto Warm Autoimmune Hemolytic Anemia in Vancouver Warm Autoimmune Hemolytic Anemia in Montreal Warm Autoimmune Hemolytic Anemia in Calgary Warm Autoimmune Hemolytic Anemia in Edmonton Warm Autoimmune Hemolytic Anemia in Ottawa Warm Autoimmune Hemolytic Anemia in Winnipeg Warm Autoimmune Hemolytic Anemia in Quebec City Warm Autoimmune Hemolytic Anemia in Hamilton Warm Autoimmune Hemolytic Anemia in Kitchener Warm Autoimmune Hemolytic Anemia in London Warm Autoimmune Hemolytic Anemia in Halifax Warm Autoimmune Hemolytic Anemia in New York Warm Autoimmune Hemolytic Anemia in Los Angeles Warm Autoimmune Hemolytic Anemia in Chicago Warm Autoimmune Hemolytic Anemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease